News & Updates

Show Multimedia Only
DISCREET highlights apremilast potential for genital psoriasis DISCREET highlights apremilast potential for genital psoriasis

DISCREET highlights apremilast potential for genital psoriasis

22 Oct 2024 byAudrey Abella

Individuals with psoriasis creeping into their intimate areas may find relief from apremilast, as shown by the week-32 improvements in multiple disease parameters in the phase III DISCREET study.

22 Oct 2024
IV iron replacement safe, effective for anemia after variceal bleed in cirrhosis patients

IV iron replacement safe, effective for anemia after variceal bleed in cirrhosis patients

21 Oct 2024

Patients with cirrhosis with iron deficiency anemia after variceal bleed (VB) can rely on the efficacy and safety of intravenous (IV) iron replacement, reports a study.

21 Oct 2024
TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment

TIL therapy still effective in advanced melanoma despite prior anti-PD-(L)1 treatment

21 Oct 2024 byStephen Padilla

The clinical response or survival benefit derived by patients with advanced cutaneous melanoma from adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) does not wane even with prior antiprogrammed cell death protein 1/programmed death-ligand 1 (anti-PD-[L]1) treatment, according to a study. TIL therapy also provides benefits in the second-line setting after anti-PD-(L)1 treatment.

21 Oct 2024
Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients

Real-world study favours ritonavir-based regimens for hospitalized COVID-19 patients

21 Oct 2024 byAudrey Abella

In a real-world analysis evaluating four oral antiviral agents for the treatment of COVID-19, two ritonavir-based regimens fared better than molnupiravir and azvudine in reducing hospital stay among patients hospitalized for mild or moderate disease.

21 Oct 2024